Arena Pharmaceuticals, Inc. – NASDAQ:ARNA

Add to watchlist

$99.99

Market closed

Open in 1 day

+7.92%

quarter

+47.07%

year

Market Cap	N/A
Enterprise value	5.95B

P/E	-9.85
EV/Sales	110256.02
EV/EBITDA	-9.76
Price/Sales	113651.59
Price/Book	9.11
PEG ratio	0.18
EPS	-10.14

Revenue	N/A
EBITDA	-609.47M
Income	-617.43M
Revenue Q/Q	45.94%
Revenue Y/Y	-83.07%

Profit margin	-1141542.59%
Oper. margin	-1156109.26%
Gross margin	0%
EBIT margin	-1156109.26%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Profit margin
Mar 2021	0	-118.41M
Jun 2021	0	-146.09M
Sep 2021	0	-196.31M
Dec 2021	54K	-156.61M	-290025.93%

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Earnings per share (EPS)
2021-08-05	-2.21	-2.4
2021-11-04	-2.42	-3.21
2022-02-23	-2.26	-2.39

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Debt to assets
Mar 2021	1183936000	97.94M	8.27%
Jun 2021	1084659000	113.57M	10.47%
Sep 2021	901027000	100.30M	11.13%
Dec 2021	784705000	111.46M	14.21%

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Cash Flow
Mar 2021	-119.98M	227.11M	106.39M
Jun 2021	-93.83M	162.59M	12.42M
Sep 2021	-117.69M	-17.38M	7.46M
Dec 2021	-120.49M	-50.91M	9.12M

Arena Pharmaceuticals alternative data

Arena Pharmaceuticals
Employees

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Employee count
Aug 2023	448
Sep 2023	448
Oct 2023	448
Nov 2023	448
Dec 2023	448
Jan 2024	448
Feb 2024	448
Mar 2024	448
Apr 2024	448
May 2024	448
Jun 2024	448
Jul 2024	448

Arena Pharmaceuticals
Insider Trading

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Insider trades (number of shares)
Period	Buy	Sel
Dec 2020	10	14261
Jan 2021	0	181081
Feb 2021	0	37524
Jun 2021	0	1223
Aug 2021	3000	17500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	16 Aug 2021	MUNSHI AMIT director, officer: President and CEO director, officer: President an..	Common Stock	1,000	$48.19	$48,190
Purchase	12 Aug 2021	MUNSHI AMIT director, officer: President and CEO director, officer: President an..	Common Stock	1,000	$50.41	$50,410
Purchase	10 Aug 2021	MUNSHI AMIT director, officer: President and CEO director, officer: President an..	Common Stock	1,000	$52.92	$52,915
Option	3 Aug 2021	LISICKI ROBERT officer: EVP, Chi..	Common Stock	17,500	$40.95	$716,625
Sale	3 Aug 2021	LISICKI ROBERT officer: EVP, Chi..	Common Stock	17,500	$60.02	$1,050,350
Option	3 Aug 2021	LISICKI ROBERT officer: EVP, Chi..	Employee Stock Option (right to buy)	17,500	$40.95	$716,625
Sale	15 Jun 2021	DALLAS JAYSON DONALD ALEXANDER director director	Common Stock	1,223	N/A	N/A
Option	16 Mar 2021	STELZER LAURIE officer: EVP & Ch..	Common Stock	12,600	N/A	N/A
Option	16 Mar 2021	STELZER LAURIE officer: EVP & Ch..	Performance Restricted Stock Unit	12,600	N/A	N/A
Option	15 Mar 2021	SCHMIDT JOAN officer: EVP, Gen..	Performance Restricted Stock Unit	12,600	N/A	N/A

ARNA insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Method of treating conditions related to the PGI2 receptor Filling date: 12 Apr 2021 Issue date: 30 Aug 2022	12 Apr 2021	30 Aug 2022
Application	Application PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROC- YCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF Filling date: 14 Sep 2021 Issue date: 18 Aug 2022	14 Sep 2021	18 Aug 2022
Application	Application CANNABINOID RECEPTOR MODULATORS Filling date: 17 Sep 2021 Issue date: 4 Aug 2022	17 Sep 2021	4 Aug 2022
Grant	Grant Utility: 5-HT.sub.2C receptor agonists and compositions and methods of use Filling date: 14 Apr 2020 Issue date: 26 Jul 2022	14 Apr 2020	26 Jul 2022
Application	Application COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Filling date: 1 Jul 2021 Issue date: 26 May 2022	1 Jul 2021	26 May 2022
Grant	Grant Utility: Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto Filling date: 6 Dec 2018 Issue date: 24 May 2022	6 Dec 2018	24 May 2022
Application	Application METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR Filling date: 8 Jan 2020 Issue date: 12 May 2022	8 Jan 2020	12 May 2022
Application	Application METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR Filling date: 26 Nov 2019 Issue date: 27 Jan 2022	26 Nov 2019	27 Jan 2022
Application	Application CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) FOR USE IN SIPI RECEPTOR-ASSOCIATED DISORDERS Filling date: 14 Jul 2021 Issue date: 6 Jan 2022	14 Jul 2021	6 Jan 2022
Grant	Grant Utility: Cannabinoid receptor modulators Filling date: 24 Sep 2019 Issue date: 4 Jan 2022	24 Sep 2019	4 Jan 2022

Arena Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q3 2021 4 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 5 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 5 May 2021	Q1 2021 Earnings Call Transcript
Q4 2020 23 Feb 2021	Q4 2020 Earnings Call Transcript

ARNA earnings call transcripts

Arena Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Amit D. Munshi M.B.A. (1968) Pres, Chief Executive Officer & Director	57	$1,220,000
Mr. Vincent E. Aurentz (1968) Executive Vice President & Chief Bus. Officer	57	$692,820
Mr. Robert Lisicki (1968) Executive Vice President & Chief Commercial Officer	57	$686,630
Ms. Laurie D. Stelzer (1968) Executive Vice President & Chief Financial Officer	57	$630,760
Ms. Joan Schmidt (1964) Executive Vice President, Gen. Counsel & Sec.	61	$624,610

Arena Pharmaceuticals
Latest News

Friday, 11 March 2022
11:04	Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals	Market Watch
Wednesday, 9 March 2022
06:24	7 Biotech Stocks With Key Catalysts in March	InvestorPlace
Monday, 28 February 2022
15:05	11 Marijuana Stocks on Fire to Close February	Schaeffers Research
Thursday, 24 February 2022
19:15	Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus	Zacks Investment Research
Thursday, 17 February 2022
19:30	Top 3 weed stocks to put on your watch list this year	Invezz
Tuesday, 18 January 2022
16:33	Pharma Giants Go After $10 Billion Market With RSV Drugs	GuruFocus
Thursday, 23 December 2021
12:01	Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment	Market Watch
Wednesday, 22 December 2021
11:28	Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?	Zacks Investment Research
Wednesday, 15 December 2021
22:13	Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022	Seeking Alpha
Tuesday, 14 December 2021
10:44	Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline	Zacks Investment Research
10:44	Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?	Zacks Investment Research
07:28	Pfizer's acquisition of Arena "shows big pharma's interest in cannabinoid medicines"	Proactive Investors
Monday, 13 December 2021
17:44	Why Arena Pharmaceuticals Stock Skyrocketed 80% Today	The Motley Fool
15:21	Arena Pharmaceuticals up 90% after acquisition announcement	Invezz
13:18	Pfizer stock heads toward record after $6.7 billion takeover of Arena; deal ‘makes strategic sense to us,' says analyst	Market Watch
11:57	ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today	InvestorPlace
11:44	How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal	Benzinga
10:18	Why Arena Pharmaceuticals Stock Is Soaring Today	Benzinga
08:44	Analysts: Pfizer to 'capitalize' on experimental colitis treatment in Arena deal	Market Watch
08:41	Arena Pharmaceuticals Stock (ARNA): Why The Price Surged Today	Pulse2
08:40	Pfizer to Buy Arena Pharmaceuticals in $6.7 Billion Deal	Barrons
07:27	After Blood Cancer, Pfizer Now Bolsters Its Inflammatory Diseases Pipeline With $6.7B Arena Deal	Benzinga
06:50	Pfizer to Buy Arena Pharmaceuticals in $6.7 Billion Deal	Barrons
06:39	Pfizer to buy Arena Pharmaceuticals for $6.7 billion	Reuters
06:29	Pfizer to acquire Arena Pharmaceuticals in deal valued at about $6.7 billion	Market Watch
Friday, 5 November 2021
12:58	Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil	Zacks Investment Research
Thursday, 4 November 2021
23:07	Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
22:06	Arena Pharmaceuticals, Inc. (ARNA) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 14 October 2021
08:44	Arena Pharmaceuticals: A Speculative Buy To Play The Upcoming Etrasimod's Data-Readout	Seeking Alpha
Wednesday, 8 September 2021
12:25	7 Busted Biotech Stocks Due for a Rebound	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of Arena Pharmaceuticals stock today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $99.99.
When is Arena Pharmaceuticals's next earnings date?

Unfortunately, Arena Pharmaceuticals's (ARNA) next earnings date is currently unknown.
Does Arena Pharmaceuticals pay dividends?

No, Arena Pharmaceuticals does not pay dividends.
What is Arena Pharmaceuticals's stock symbol?

Arena Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ARNA".
What is Arena Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Arena Pharmaceuticals?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Arena Pharmaceuticals's key executives?
Arena Pharmaceuticals's management team includes the following people:
- Mr. Amit D. Munshi M.B.A. Pres, Chief Executive Officer & Director(age: 57, pay: $1,220,000)
- Mr. Vincent E. Aurentz Executive Vice President & Chief Bus. Officer(age: 57, pay: $692,820)
- Mr. Robert Lisicki Executive Vice President & Chief Commercial Officer(age: 57, pay: $686,630)
- Ms. Laurie D. Stelzer Executive Vice President & Chief Financial Officer(age: 57, pay: $630,760)
- Ms. Joan Schmidt Executive Vice President, Gen. Counsel & Sec.(age: 61, pay: $624,610)
How many employees does Arena Pharmaceuticals have?

As Jul 2024, Arena Pharmaceuticals employs 448 workers.
When Arena Pharmaceuticals went public?

Arena Pharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 28 Jul 2000.
What is Arena Pharmaceuticals's official website?

The official website for Arena Pharmaceuticals is arenapharm.com.
Where are Arena Pharmaceuticals's headquarters?

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Dr, San Diego, CALIFORNIA.
How can i contact Arena Pharmaceuticals?

Arena Pharmaceuticals's mailing address is 6154 Nancy Ridge Dr, San Diego, CALIFORNIA and company can be reached via phone at +1 858 453 7200.

Arena Pharmaceuticals, Inc.

arenapharm.com

Exchange:

NASDAQ

Full time employees:

448

Industry:

Biotechnology

Sector:

Healthcare

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

+1 858 453 7200

6154 Nancy Ridge Dr
San Diego, CALIFORNIA 84060

CIK: 0001080709
ISIN: US0400476075
CUSIP: 040047607